RxDoctor Payments Data

Adelle Nicolas

Family · San Diego, CANPI 1285996629

Payments from drug & device makers

$1,446in general payments, 2019–2025

Across 37 payments — averaging $39.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$285
  • Amgen$222
  • AstraZeneca$203
  • Exact Sciences$141
  • Corcept Therapeutics$141
  • Novo Nordisk$109
  • plus $345 from 9 others

What the payments were for

  • Speaking & faculty fees$151%
  • Food & beverage$1,43199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK4$285
Amgen2$222
AstraZeneca6$203
Exact Sciences5$141
Corcept Therapeutics1$141
Novo Nordisk5$109
Bayer1$104
Merck3$59
Pfizer3$52
AbbVie2$38
Astellas Pharma US Inc1$24
Lilly USA, LLC1$24
Mckesson Medical-surgical, Inc.1$15
Boehringer Ingelheim1$15
Phathom Pharmaceuticals, Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,446 in reported general payments places this provider in the 80th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$29,683
Medicare patients
195
Services billed
324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen50$992
SynthroidLevothyroxine Sodium18$566
Levothyroxine Sodium48$539
Atorvastatin Calcium57$495
Pantoprazole Sodium20$473
Omeprazole18$350
Gabapentin13$340
Rosuvastatin Calcium26$315
Losartan Potassium29$304
Albuterol Sulfate HfaAlbuterol Sulfate13$293
Zolpidem Tartrate39$266
Metformin Hcl27$263
Tamsulosin Hcl15$253
Metoprolol Succinate13$246
Famotidine19$238

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieSynthroid$38$56618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,634 family providers in California.

Other family in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →